Drug Trial Radar · NCT07650084
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension
Last checked: Nov 20, 2026Latest source record: Jun 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
Nov 21, 2025
Primary completion
Aug 27, 2027
Study completion Jun 2, 2028
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jun 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
Conditions
- Refractory Chronic Cough
Interventions
BLU-5937Drug
Oral administration of BLU-5937 Tablets.
PlaceboDrug
Oral administration of matching placebo for BLU-5937 Tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 24-Hour Cough FrequencyTime frame: Week 24
- Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) up to Week 24Time frame: Up to Week 24
- Number of Participants with Adverse Events of Medical Interest (AEMIs) up to Week 24Time frame: Up to Week 24
- Number of Participants with Study Treatment Discontinuation due to AEs and SAEs up to Week 24Time frame: Up to Week 24
- Number of Participants with AEs and SAEs Leading to Study Withdrawal up to Week 24Time frame: Up to Week 24
- Change from Baseline in Vital Signs: Systolic and Diastolic Blood Pressure (millimeters of mercury [mm Hg]) at Week 24Time frame: Baseline, Week 24
- Change from Baseline in Vital Sign: Pulse (beats per minute) at Week 24Time frame: Baseline, Week 24
- Change from Baseline in Vital Sign: Respiratory Rate (breaths per minute) at Week 24Time frame: Baseline, Week 24
- Change from Baseline in Vital Sign: Body Temperature (degrees Celsius) at Week 24Time frame: Baseline, Week 24
- Change from Baseline in Vital Sign: Weight (kilograms [kg]) at Week 24Time frame: Baseline, Week 24
- Change from Baseline in Male Reproductive Hormone: Total Testosterone (nanomoles per liter [nmol/L]) at Week 24Time frame: Baseline, Week 24
- Change from Baseline in Male Reproductive Hormones: Follicle-Stimulating Hormone [FSH] and Luteinizing Hormone [LH] (international units per liter [IU/L]) at Week 24Time frame: Baseline, Week 24
- Change from Baseline in Male Reproductive Hormone: Inhibin B (nanograms per liter [ng/L]) at Week 24Time frame: Baseline, Week 24
- Change from Baseline in Hematology Parameter: Red Blood Cell (RBC) Count (10^12 cells per liter) at Week 24Time frame: Baseline, Week 24
- Change from Baseline in Hematology Parameters: Hemoglobin and Mean Corpuscular Hemoglobin Concentration (MCHC) (grams per liter [g/L]) at Week 24Time frame: Baseline, Week 24
- Change from Baseline in Hematology Parameter: Hematocrit (percentage) at Week 24Time frame: Baseline, Week 24
- Change from Baseline in Hematology Parameter: Mean Corpuscular Volume (MCV) (femtoliters [fL]) at Week 24Time frame: Baseline, Week 24
- Change from Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin (MCH) (picograms per cell [pg/cell]) at Week 24Time frame: Baseline, Week 24
- Change from Baseline in Hematology Parameter: Red Cell Distribution Width (RDW) (percentage) at Week 24Time frame: Baseline, Week 24
- Change from Baseline in Hematology Parameters: White Blood Cell (WBC) Count (neutrophils, lymphocytes, monocytes, eosinophils, and basophils) and Platelet Count (10^9 cells per liter) at Week 24Time frame: Baseline, Week 24
- Change from Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma-Glutamyl Transferase (GGT) (units per liter [U/L]) at Week 24Time frame: Baseline, Week 24
- Change from Baseline in Clinical Chemistry Parameters: Alkaline Phosphatase (ALP) and Creatine Kinase (CK) (international units per liter [IU/L]) at Week 24Time frame: Baseline, Week 24
- Change from Baseline in Clinical Chemistry Parameters: Total Bilirubin, Direct and Indirect Bilirubin, and Creatinine (micromoles per liter) at Week 24Time frame: Baseline, Week 24
- Change from Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Chloride, Calcium, Magnesium, Bicarbonate, Glucose, and Blood Urea Nitrogen (BUN) (millimoles per liter [mmol/L]) at Week 24Time frame: Baseline, Week 24
- Change from Baseline in Clinical Chemistry Parameters: Protein and Albumin (grams per liter [g/L]) at Week 24Time frame: Baseline, Week 24
- Change from Baseline in Clinical Chemistry Parameter: Estimated Glomerular Filtration Rate (eGFR) (milliliters per minute per 1.73 meters squared [mL/min/1.73 m^2]) at Week 24Time frame: Baseline, Week 24
- Change from Baseline in Clinical Chemistry Parameters: Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT) (seconds) at Week 24Time frame: Baseline, Week 24
- Change from Baseline in Electrocardiogram (ECG) Value: Heart Rate (beats per minute) at Week 24Time frame: Baseline, Week 24
- Change from Baseline in ECG Value: PR Interval, QT Interval, RR Interval, QRS Interval, and Corrected QT Interval Using Fridericia's Formula (QTcF) (milliseconds) at Week 24Time frame: Baseline, Week 24
Locations
38 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Beijing, China · Recruiting
GSK Investigational Site
Changsha, China · Recruiting
GSK Investigational Site
Chengdu, China · Recruiting
GSK Investigational Site
Chengdu, China · Recruiting
GSK Investigational Site
Chongqing, China · Recruiting
GSK Investigational Site
Dongguan, China · Recruiting
GSK Investigational Site
Ganzhou, China · Recruiting
GSK Investigational Site
Guangzhou, China · Recruiting
GSK Investigational Site
Guangzhou, China · Recruiting
GSK Investigational Site
Guilin, China · Recruiting
GSK Investigational Site
Hangzhou, China · Recruiting
GSK Investigational Site
Hefei, China · Recruiting
GSK Investigational Site
Hefei, China · Recruiting
GSK Investigational Site
Hohhot, China · Recruiting
GSK Investigational Site
Huizhou, China · Recruiting
GSK Investigational Site
Huizhou, China · Recruiting
GSK Investigational Site
Jiangsu, China · Recruiting
GSK Investigational Site
Jinan, China · Recruiting
GSK Investigational Site
Kunming, China · Recruiting
GSK Investigational Site
Liuzhou, China · Recruiting
GSK Investigational Site
Meizhou, China · Recruiting
GSK Investigational Site
Nanchang, China · Recruiting
GSK Investigational Site
Pingxiang, China · Recruiting
GSK Investigational Site
Shanghai, China · Recruiting
GSK Investigational Site
Shanghai, China · Recruiting
GSK Investigational Site
Shanghai, China · Recruiting
GSK Investigational Site
Shenyang, China · Recruiting
GSK Investigational Site
Shenzhen, China · Recruiting
GSK Investigational Site
Taizhou, China · Recruiting
GSK Investigational Site
Ürümqi, China · Recruiting
GSK Investigational Site
Weifang, China · Recruiting
GSK Investigational Site
Wuxi, China · Recruiting
GSK Investigational Site
Xiamen, China · Recruiting
GSK Investigational Site
Yangzhou, China · Recruiting
GSK Investigational Site
Yinchuan, China · Recruiting
GSK Investigational Site
Zhanjiang, China · Recruiting
GSK Investigational Site
Zhengzhou, China · Recruiting
GSK Investigational Site
Leshan, Sichuan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.